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Abstract
Macrocycles have attracted significant attention in drug discovery recently. In fact, a few de novo 
designed macrocyclic kinases inhibitors are currently in clinical trials with good potency and 
selectivity for their intended target. In this paper, we have successfully engaged a structure-based 
drug design approach to discover macrocyclic pyrimidines as potent Mer tyrosine kinase 
(MerTK)-specific inhibitors. An enzyme-linked immunosorbent assay (ELISA) in a 384-well 
format was employed to evaluate the inhibitory activity of macrocycles in a cell-based assay 
assessing tyrosine phosphorylation of MerTK. Through SAR studies, analogue 11 (UNC2541) 
was identified as a potent and MerTK-specific inhibitor and exhibits sub-micro molar inhibitory 
activity in the cell-based ELISA assay. In addition, an X-ray structure of MerTK protein in 
complex with 11 was resolved to show that these macro-cycles bind in the MerTK ATP pocket.
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Graphical abstract
A structure-based drug design approach led to macrocyclic pyrimidines as potent Mer tyrosine 
kinase (MerTK)-specific inhibitors. Through SAR studies, analogue 11 (UNC2541) was identified 
as a key compound and exhibits sub-micro molar inhibitory activity in the cell-based enzyme-
linked immunosorbent assay (ELISA). In addition, an X-ray structure of MerTK protein in 
complex with 11 was resolved to show that these macrocycles bind in the MerTK ATP pocket.
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Macrocycles, especially de novo designed macrocycles, have recently gained attention in 
drug discovery due to the new physicochemical properties and broader intellectual property 
(IP) that they may provide.1-3 In macrocycles, cyclization leads to a structural 
preorganization which can increase both binding affinity and selectivity by engaging targets 
through numerous and spatially distributed binding interactions.1,4 A few macrocyclic 
kinase inhibitors are currently in clinical trials with good potency and selectivity for their 
intended target.5-7 We have been interested in Mer tyrosine kinase (MerTK) as a therapeutic 
target8,9 and have developed several MerTK inhibitors with varying selectivity profiles.10-14 
The most advanced compound among these inhibitors is UNC2025 which is a potent and 
highly orally bioavailable MerTK inhibitor.14 It is also equally potent against FMS-like 
tyrosine kinase (Flt3). This dual inhibitory activity of UNC2025 is desirable for certain 
diseases such as AML, however, inhibition of Flt3 has been associated with hematopoietic 
toxicity15,16 and is therefore inadvisable for other applications of MerTK inhibitors. The 
new pyrrolopyrimidine macrocycles that we have developed recently share the same 
undesired selectivity profile.17 In this paper, we will present a new type of MerTK-specific 
inhibitor—macrocyclic pyrimidines.
We have recently discovered substituted-pyrimidines as novel MerTK specific inhibitors via 
a structure-based drug design approach.12 Based on our published X-ray crystal structure of 
MerTK in complex with 1 (Figures 1a and 1b), the butyl side chain and the cyclohexyl 
alcohol are close to each other and well-positioned to form a macrocycle. One example of 
this design is compound 2 (Figure 1c), which has a hydrogen donor, an amino group, at the 
same position as the hydroxyl group in 1. The macrocycle is connected by an amide bond 
and the cyclohexyl ring has been opened to eliminate the chance to introduce new 
stereogenic centers. Compound 2 fits the MerTK docking model and is predicted to retain 
three key hydrogen bonds with MerTK protein (Figure 1d, two with the hinge area (F673 
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and P672) and one with either D741, R727, or N728). Since substituted-pyrimidines show 
some selectivity for MerTK over Flt3 (e.g. compound 1 is 14-fold more active against 
MerTK versus Flt3),12 we were interested to see if macrocycles based on this scaffold could 
improve MerTK inhibitory activity and/or the selectivity profile over other TAM family 
members and Flt3.
The syntheses of the designed macrocyclic compounds are straight forward. A general 
synthetic route is shown in Scheme 1 (see Supporting Information for details). 
Commercially available 2,4-dichloropyrimidine-5-carbonyl chloride reacted with an amine 
or alcohol to form the amide/ester I. In a one-pot reaction Boc protected amino acids with 
differing length alkyl chains and various diamines were attached to the pyrimidine core to 
provide intermediate II. The macrocycle was closed using an intramolecular amide coupling 
reaction, followed by cleavage of the Boc protecting group to yield the desired macrocycles 
III. To explore SAR at the R′ position, the starting acid chloride was first converted into an 
ethyl ester. After the formation of the desired macrocycle, the ethyl ester was hydrolyzed 
under basic conditions and the resulting free acid was converted to the final amide IV via an 
amide bond coupling reaction and cleavage of the Boc protecting group.
Compound 2 was synthesized using the route presented in Scheme 1 and was tested using 
in-house microfluidic capillary electrophoresis (MCE) assays at the ATP Kms (details see 
supporting information Table S1).18-20 As shown in Table 1, compound 2 demonstrated 
exceptional selectivity over Flt3 (110-fold vs 14-fold for compound 1) along with weaker 
activity against MerTK (12-fold lower IC50 than compound 1). To improve the MerTK 
activity of compound 2, we initially explored the ring size of the macrocycle since this 
would simultaneously vary the position of the hydrogen-bond donor, the amino group, and 
the flexibility of the ring. As shown in Table 1, when m = 1, the inhibitory activity of 
macrocycles varied depending on the ring size. Compound 2 (n = 2) was 3-fold more potent 
than compound 3 (n = 1), however, compound 4 (n = 3) was 12-fold less active than 
compound 2. When n ≥ 4, the potency of the macrocycles was improved as the macrocyclic 
ring size was increased (compounds 4-7). The trend was also evident when m = 2. 
Compound 8 (n = 1) was a weak MerTK inhibitor with micromolar potency while 
compound 11 (UNC2541) (n = 4) was very potent with a low nanomolar IC50 against 
MerTK. The MerTK inhibitory activities of compound 9 (n = 2) and 10 (n = 3) were 
intermediate. When the macrocyclic ring became larger (n = 5 or 6), the MerTK activity of 
the corresponding analogues 12 and 13 was retained, however, the selectivity over Flt3 
decreased (73-fold for 11 vs 59-fold for 12 & 19-fold for 13). In general, most of the 
analogues had excellent selectivity for MerTK over Flt3 and good selectivity over Axl and 
Tyro3. To evaluate the inhibitory activity of these compounds in a cell-based assay of 
tyrosine phosphorylated MerTK (pMerTK), we used a 384-well format enzyme-linked 
immunosorbent assay (ELISA),17 in which HEK293 cells are transfected with a cDNA 
encoding chimeric protein consisting of the extracellular and transmembrane domains from 
the epidermal growth factor receptor (EGFR) and the MerTK intracellular kinase domain. 
Activity is then stimulated with EGF. A chimeric protein was utilized because consistent 
stimulation of native MerTK kinase with the complex, natural ligand (GAS6 plus PtdSer) 
was not practical. Compound 11 proved to be the most active in this pMerTK ELISA assay 
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with an EC50 510 nM. The 100-fold IC50 shift from the MCE assay to the pMerTK ELISA 
assay isn't unexpected due to the ATP concentration difference (5.0 μM in the MCE assay vs 
low millimolar range in the pMerTK ELISA assay).
With the optimal ring size and linker of macrocycle 11, the SAR at the R′ position was 
explored using the synthetic route presented in Scheme 1 (Table 2). Introducing a larger and 
basic dimethyl amine group in the para-position of the benzyl group at the R′ position didn't 
affect the activity or selectivity of the corresponding analogue 14 in either the MCE or 
pMerTK ELISA assays. However, 3,5-dimethoxyl benzyl group at the R′ position led to a 
6-fold less active analogue 15. A para-substituted phenyl group at the same position (16–18) 
yielded analogues with dramatically diminished selectivity for MerTK over Flt3 although 
their MerTK enzymatic activities were similar to 11. No MerTK cellular activity was 
observed for these derivatives at a concentration of 1.0 μM in the pMerTK ELISA assay. 
When placing heterocycles such as 3-pyridyl and 4-pyridyl at the R′ position, the resulting 
analogues 19 and 20 had similar inhibitory enzymatic activity and selectivity for MerTK 
over Flt3 compared to 11, and again, no cellular activity was observed at a concentration of 
1.0 μM. 2-Pyridyl at the same position led to a 5-fold less active analogue 21. However, 
when 3-pyridyl at the R′ site was further substituted at the para-position with 1-pyrazole, 
the resulting analogue 22 was 4-fold more active than the parental analogue 19 and exhibited 
improved Flt3 selectivity (193-fold for 22 vs 152-fold for 19) and cellular activity (IC50 420 
nM). Saturated heterocycles such as 4-piperidine (23) and 4-tetrahydropyran (24) were also 
tolerated at this position. Analogues 23 and 24 were equally potent to 19 in either the MCE 
or pMerTK ELISA assays. Similarly, further substitution on the nitrogen of 4-piperidine 
with a benzyl group at the R′ position increased the activity of the corresponding analogue 
25, especially in the pMerTK ELISA assay (IC50 250 nM).
The weak cellular activity of these analogues may be due to the polar α-amino amide linker. 
Therefore, we varied the linker of the macrocycle to explore if any other linker would 
improve the cellular activity (Table 3). When the primary amine was protected by a Boc 
group (26) or removed (27), the activity against MerTK was dramatically reduced (over 10-
fold in the MCE assay compared to compound 11) due to lack of the key hydrogen bond 
with either D741 or R727 or N728. On the other hand, a similarly active compound 28 was 
obtained by substitution of the primary amine to yield a secondary amino group. 
Unfortunately, the cellular activity of 28 wasn't improved by the reducing the polarity and 
removing a hydrogen bond donor of the amino group because these changes decreased the 
MerTK inhibitory activity of 28 (3-fold) as well. In addition, replacement of the amide 
group in 11 with a less polar ester group such as in 29, preserved activity in either the 
MerTK MCE or pMerTK ELISA assays. Another attempt to reduce the polarity while 
retaining the hydrogen bond donor property of the α-amino amide linker was to replace it 
with a secondary hydroxyl group. Three analogues were prepared (30–32). The ring size and 
the position of the hydrogen bond donor of analogue 30 was the same as analogue 10. Both 
analogues had similar MerTK activity, however, the Flt3 selectivity of 30 was diminished 
from 89-fold (10) to 24-fold (30). The activity and selectivity were worse for analogue 31. 
Although the ring size and the position of the hydrogen donor of 31 was the same as 12, 
analogue 31 was 34-fold less active than 12 in the MerTK MCE assay and only had 5-fold 
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selectivity over Flt3. Interestingly, analogue 32 had the same ring size and the same position 
of its hydrogen bond donor as 3, was 10-fold more active than 3 in the MCE assay. It also 
had weak activity in the pMerTK ELISA assay (IC50 600 nM). Linkers containing oxygen as 
the hydrogen bond acceptor such as epoxide (33) or ether (34 & 35), showed much lower 
MerTK inhibitory activity. More rigid macrocycles containing a phenyl ring resulted in 
analogues 36 and 37. Analogue 36 had the same-sized macrocycle with its hydrogen bond 
acceptor, an amino group, at the same position as 22. However, it was 27-fold less active 
than 22 in the MCE assay. Similarly, analogue 37 was 7-fold weaker than 25 with similar 
selectivity over Flt3. Overall, the amide linker was optimal in this series.
To confirm our initial design strategy and gain better insight into ligand-protein interactions, 
we solved the X-ray structure of MerTK in complex with 11 at a resolution of 2.23 Å. 
Overall, the structure corroborated the preliminary docking hypothesis (Figure 1). However, 
there was one notable difference. In the crystal structure (Figure 2), both the carbonyl and 
primary amine groups of the macrocycle pointed outward with respect to the residues R727, 
N728 and D741, while we had hypothesized that the main interaction in this region would 
occur between only the primary amine and the above three residues. Our docking hypothesis 
was based on previous non-macrocyclic amino-pyridines, such as 1, which all needed either 
a hydroxyl or a primary amino group to gain potency through interactions with R727, N728 
or D741.
In addition, we used a panel of 30 kinases which emphasized tyrosine kinases along with 
selected serine/threonine kinases to assess the selectivity of promising compounds over other 
kinase families.8-9 Analogue 11 was evaluated in this panel at a concentration 100 fold 
above its Mer IC50 (Figure 3) (detailed in supplemental materials). Similar to its open-
chained analogue (substituted pyrimidines),8 five tyrosine kinases were inhibited greater 
than 50% in the presence of 430 nM 11. However, three additional serine/threonine kinases 
were inhibited greater than 50% and were not inhibited by 1 under the same conditions.
In summary, novel and potent macrocyclic pyrimidines have been discovered as MerTK 
kinase inhibitors via a structure-based drug design approach. The binding mode of these 
macrocycles was confirmed by an X-ray structure of MerTK protein complexed with 
analogue 11. A high-throughput ELISA assay was also employed to evaluate the inhibitory 
activity of the compounds in a cell-based assay of tyrosine phosphorylated MerTK. These 
macrocycles proved to be MerTK-selective within the TAM family and over Flt3. However, 
the selectivity over other kinase families and the cellular activity of these macrocycles need 
to be further improved to yield a lead compound worthy of further progression in this series.
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Figure 1. 
a. Structure of 1; b. X-ray crystal structure of 1 in complex with MerTK (kinase domain) 
(PDB ID code 4MHA); c. Structure of 2; d. Docking model of macrocyclic pyrimidine 2.
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Scheme 1. 
The synthetic route for macrocyclic compounds
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Figure 2. 
a. Structure of 11; b&C. X-ray crystal structure of 11 in complex with Mer (kinase domain) 
(PDB ID code 5K0X).
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Figure 3. 
Kinase Tree
McIver et al. Page 11
ChemMedChem. Author manuscript; available in PMC 2018 February 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
McIver et al. Page 12
Table 1
Preliminary SAR of macrocycle ring size
IC50 (nM)a EC50 (nM)a
Compound n m MerTK Axl Tyro3 Flt3 pMerTK ELISA
2 2 1 61 ± 46 1600 ± 370 1800 ± 970 6700 ± 6300 >1000
3 1 1 200 ± 140 21000 ± 7300 8200 ± 7000 inactive >1000
4 3 1 760 ± 330 28000 ± 2900 inactive inactive >1000
5 4 1 230 ± 54 7800 ± 2800 8500 ± 5300 14000 ± 14000 >1000
6 5 1 91 ± 28 2700 ± 1000 3400 ± 1500 10000 ± 1800 >1000
7 6 1 62 ± 25 1100 ± 340 2700 ± 2000 2100 ± 560 >1000
8 1 2 3200 ± 2500 inactive 24000 ± 3300 inactive >1000
9 2 2 140 ± 96 4000 ± 1400 6900 ± 5800 inactive >1000
10 3 2 36 ± 14 1700 ± 350 1600 ± 910 3200 ± 610 >1000
11 4 2 4.4 ± 0.5 120 ± 60 220 ± 82 320 ± 11 510 ± 300
12 5 2 4.1 ± 0.2 130 ± 16 150 ± 4.4 240b ND
13 6 2 6.2 ± 3.3 170 ± 13 160 ± 110 120 ± 36 790 ± 110
aValues are the mean of two or more independent assays ± SD.
bOnly test once.
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Table 2
SAR Study of the R′ position
Compound R′ IC50 (nM)a EC50 (nM)a
MerTK Axl Tyro3 Flt3 pMerTK ELISA
14 6.4 ± 1.3 180 ± 98 330 ± 110 740 ± 210 470 ± 79
15 25 ± 21 500 ± 30 920 ± 470 5900 ± 470 >1000
16 6.0 ± 2.8 100 ± 34 340 ± 210 49 ± 11 >1000
17 9.5 ± 2.9 300 ± 130 800 ± 340 38 ± 43 >1000
18 4.3 ± 1.1 83 ± 54 150 ± 27 22 ± 3.1 >1000
19 6.3 ± 3.3 330 ± 270 340 ± 230 960 ± 410 >1000
20 4.4 ± 4.1 110 ± 41 360 ± 230 780 ± 110 >1000
21 22 ± 16 540 ± 170 680 ± 470 890 ± 260 >1000
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Compound R′ IC50 (nM)a EC50 (nM)a
MerTK Axl Tyro3 Flt3 pMerTK ELISA
22 1.5 ± 0.4 72 ± 31 86 ± 2.1 290 ± 25 420b
23 6.5 ± 2.0 150 ± 66 290 ± 220 850 ± 280 >1000
24 14 ± 8.5 300 ± 89 970 ± 680 860 ± 220 >1000
25 2.9 ± 1.9 50 ± 22 150 ± 200 730 ± 260 250 ± 28
aValues are the mean of two or more independent assays ± SD.
bOnly test once.
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Table 3
Exploration of different macrocycle linkers
Compound Structure IC50 (nM)a EC50 (nM)a
Mer Axl Tyro3 Flt3 pMerTK ELISA
26 54 ± 2.7 1300 ± 190 2200 ± 350 inactive >1000
27b 59 670 2300 4500 750
28 11 ± 2.7 210 ± 92 850 ± 350 840 ± 350 410 ± 140
29 3.9 ± 0.1 220 ± 11 190 ± 49 65 ± 13 430 ± 42
30b 68 1600 1500 1600 >1000
31b 140 1300 2500 630 >1000
32 21b 920b 1100b 900b 600 ± 76
33 480 ± 150 4400 ± 1100 9200 ± 4100 3100 ± 1700 ND
34 770 ± 600 20170±17020 17350 ± 15500 20080 ± 17190 ND
35 14000 ± 10000 inactive inactive inactive ND
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Compound Structure IC50 (nM)a EC50 (nM)a
Mer Axl Tyro3 Flt3 pMerTK ELISA
36 40 ± 13 300 ± 150 670 ± 470 9700 ± 6500 >1000
37 21 ± 7.0 590 ± 340 1200 ± 1500 15140 ± 21010 >1000
aValues are the mean of two or more independent assays ± SD.
bOnly test once.
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